Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
Rhea-AI Summary
Nasus Pharma (NYSE: NSRX) announced on October 8, 2025 expanded agreements with Aptar France and AptarGroup to support development and planned commercialization of NS002, an intranasal powder epinephrine candidate.
The collaboration secures a commercially proven Unit Dose System technology, access to Aptar's manufacturing, supply‑chain and technical expertise, and establishes a framework to support regulatory submissions to the FDA and EMA, aiming to accelerate NS002's path to market and reduce development risk.
Positive
- Secured commercially proven Unit Dose System technology
- Access to Aptar manufacturing and supply‑chain capabilities
- Framework to support regulatory submissions to FDA and EMA
- Collaboration intended to accelerate NS002 development to commercialization
Negative
- None.
Insights
Nasus secured a manufacturing and regulatory partner to de‑risk NS002 development and support commercialization plans.
Nasus Pharma partnered with Aptar to supply a proven Unit Dose System and end‑to‑end development and manufacturing support for its intranasal epinephrine candidate NS002. This deal links device validation, technical expertise, and supply‑chain capacity directly to ongoing clinical work, which streamlines the path from clinical development to market authorization.
Key dependencies include successful regulatory filings with the FDA and EMA, device validation and manufacturing transfer activities, and completion of required clinical data. Each dependency carries execution risk; regulatory questions, process validation issues, or supply chain delays could slow timelines or increase costs.
Watch for formal regulatory submission milestones, device validation/transfer outcomes, and manufacturing batch release data as they progress from clinical to commercial scale. The agreement announced on
Strategic collaboration with leading global manufacturer of drug delivery systems strengthens NS002's clinical and commercial roadmap with end-to-end development support and manufacturing infrastructure
TEL AVIV, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the execution of comprehensive agreements with Aptar France S.A.S. and AptarGroup, Inc. (collectively, “Aptar”), a leading global manufacturer of drug delivery systems, to support the ongoing clinical development and planned commercialization of NS002, Nasus Pharma's intranasal powder epinephrine product candidate.
"This collaboration represents a significant milestone for Nasus Pharma and for our NS002 program," said Dan Teleman, Chief Executive Officer of Nasus Pharma. "Through this collaboration, Nasus Pharma will secure a commercially proven Unit Dose System technology, providing us with a validated dosing infrastructure. This strategic relationship allows us to benefit from established regulatory pathways, manufacturing capabilities and supply chain, accelerating NS002's path to market while reducing development risks."
The collaboration establishes a comprehensive framework to support the development of NS002 through regulatory submissions with both the U.S. Food and Drug Administration (the “FDA”) and the European Medicines Agency (the “EMA”). This strategic relationship provides Nasus with access to Aptar's technical expertise and manufacturing capabilities to advance NS002 through current clinical development to commercialization in alignment with Nasus Pharma's timeline and objectives.
About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or Linkedin.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including, among other things: statements regarding the development and commercialization of NS002; the potential benefits of the collaboration with Aptar; the potential market opportunity for NS002; and that the collaboration with Aptar is accelerating NS002's path to market while reducing development risks. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s prospectus related to filed with the U.S. Securities and Exchange Commission dated August 12, 2025. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Company Contact
Nasus Pharma Ltd.
info@nasuspharma.com
Investor Contact
Arx Investor Relations
North American Equities Desk
nasus@arxhq.com
FAQ
What did Nasus Pharma announce about NS002 on October 8, 2025 (NSRX)?
How does the Aptar collaboration affect NS002 regulatory filings for NSRX?
What manufacturing benefit does Nasus Pharma gain from the Aptar deal for NSRX?
Will the Aptar agreement speed NS002's path to market for NSRX shareholders?
What specific delivery technology did Nasus secure for NS002 (NSRX)?
